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Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality worldwide and is an important public health issue. A
significant proportion of insulin-treated patients with T2DM do not reach target glycated haemoglobin (HbA1c) values, which
ultimately increases their risk of long-term microvascular and macrovascular complications. One potential option to improve
diabetes control in these patients may be the use of new insulin formulations including second-generation basal insulin
analogues such as insulin glargine 300U/mL (Gla-300). Several published randomised controlled trials have assessed the clinical
effectiveness of Gla-300, mostly versus insulin glargine 100U/mL as well as insulin degludec. However, there is limited
information about the real-world effectiveness of Gla-300 when patients are transitioned directly from neutral protamine
Hagedorn (NPH) human basal insulin. The primary objective of this study was to evaluate the effectiveness of Gla-300, defined
as the percentage of participants with an HbA1c reduction of ≥0.5%, 6 months after switching from NPH insulin, in
participants with T2DM. Secondary objectives included the safety assessment based on the percentage of patients experiencing
≥1 episodes and the number of hypoglycaemic episodes by category: severe, symptomatic, symptomatic confirmed, diurnal or
nocturnal, change in body weight, and insulin dose. A total of 469 participants completed the 6-month observation period.
Mean baseline HbA1c was 9.19%. The percentage of participants with a ≥0.5% improvement in HbA1c from baseline was 71.7%
at 6 months. Mean HbA1c decreased at 3 and 6 months by 0.77% (±0.98) and 1.01% (±1.12), respectively (p < 0:00001 versus
baseline), while fasting glycaemia decreased by 32mg/dL and 37mg/dL, respectively (p < 0:00001 versus baseline). There were
moderate increases in the doses of both Gla-300 and, if used, short-acting insulins during the 6 months of observation. The
percentage of participants with ≥1 hypoglycaemia event during the preceding 4 weeks decreased significantly from baseline to 3
and 6 months, as did the proportion with symptomatic hypoglycaemia at night (p < 0:00001 versus baseline). No participants
had severe hypoglycaemia after a switch to Gla-300. Body mass, waist and hip circumferences, and waist : hip ratio did not
change significantly. In conclusion, this large, prospective, observational study demonstrated that switching from NPH insulin
to Gla-300 resulted in a significant improvement in HbA1c, with only a moderate increase in insulin dose, a decreased risk of
hypoglycaemia, and no increase in body weight.
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1. Introduction
Type 2 diabetes mellitus (T2DM) is a major cause of morbid-
ity and mortality worldwide and a significant public health
issue. Optimising blood glucose control, especially in
insulin-treated patients, is challenging because it requires
decreasing glycated haemoglobin (HbA1c) to be balanced
against potentially increasing the risk of hypoglycaemia.
Hypoglycaemia is considered to be the major barrier to
achieving optimal control with insulin treatment of T2DM
[1]. To avoid hypoglycaemia, insulin-treated patients with
T2DM may intentionally maintain their plasma glucose
levels above recommended values [2, 3]. A significant pro-
portion of patients with T2DM do not reach target HbA1c
[4–7], which ultimately increases their risk of long-term
microvascular and macrovascular complications. Fear of
hypoglycaemia is also considered to contribute to suboptimal
glucose control [8].
One potential approach to improve HbA1c without
increasing hypoglycaemia risk in insulin-treated patients with
T2DMmay be the use of novel, safer analogue insulin formu-
lations. Switching from human neutral protamine Hagedorn
(NPH) basal insulin to long-acting, first-generation basal insu-
lin analogues significantly decreases the risk of hypoglycaemia
in patients with T2DM [9]. In addition, the use of second-
generation basal insulin analogues that have peakless pharma-
cokinetic profiles and longer duration of action was shown to
further decrease hypoglycaemic risk [10, 11]. However, no
studies have evaluated the real-world effectiveness of second-
generation basal insulins in patients transitioned from NPH
human basal insulin. Addressing this issue would be of high
clinical importance since inmany countries, including Poland,
NPH insulin is still commonly used.
2. Study Aims
The primary objective of this study was to evaluate the effec-
tiveness of insulin glargine 300U/mL (Gla-300) in partici-
pants with T2DM previously treated with NPH insulin in
Polish diabetes centres. Clinical effectiveness was defined as
the percentage of participants with an HbA1c reduction of
≥0.5% 6 months after switching to Gla-300. Secondary objec-
tives included assessment of change from baseline to months
3 and 6 in HbA1c, percentage of participants achieving indi-
vidually defined HbA1c targets, fasting blood glucose, mean
of seven-point self-monitoring of blood glucose (SMBG)
profile, insulin dose, and body weight. Safety was also evalu-
ated as a secondary endpoint according to the percentage of
participants with ≥1 event and the number of hypoglycaemic
events by category: symptomatic, confirmed (if blood
glucose ≤ 3:9mmol/L (70mg/dL)), severe (i.e., requiring the
assistance of others to administer carbohydrates or glucagon
or apply other corrective actions), diurnal (wake time), and
nocturnal (during sleep).
3. Material and Methods
3.1. Study Setting. Participating investigators were diabetol-
ogists, who routinely treat patients with T2DM at diabetes
centres/diabetologist practices and who accepted the princi-
ples of the protocol. At each centre, consecutive patients
meeting the eligibility criteria were enrolled, until the target
accrual of 500 participants was reached.
This registry was conducted in accordance with the
principles laid down by the 18th World Medical Assembly
(Helsinki, 1964) including all subsequent amendments.
Registry conduct also complied with all international
guidelines and national laws and regulations of Poland,
as well as any applicable guidelines. The sponsor (Sanofi-
Aventis Poland) ensured that all necessary regulatory submis-
sions (e.g., Institutional Review Board/Independent Ethics
Committee approval) were performed in accordance with
local regulations including those relating to data protection.
3.2. Eligibility. Eligible patients were aged ≥18 years, had
T2DM, and were switched to Gla-300 from NPH insulin
being the part of following treatment regimens: basal+oral
antidiabetic agents (OAAs), basal/bolus (bolus with either
regular human insulin or analogues), or human regular pre-
mixed (containing NPH as the basal component). Previous
NPH insulin treatment should have lasted at least 6 months
with basal, basal/bolus, or human regular premixed insulin
regimens. Previous NPH insulin treatment should have been
of at least 6 months’ duration. Patients were also required to
have a most recent HbA1c assessment from within 4 weeks
before enrolment of ≥8% while on NPH insulin treatment.
All patients gave consent to participate in this observational
study. Exclusion criteria were type 1 diabetes, participation
in another clinical study in parallel or within the past 3
months, allergy to insulin glargine, noncooperative patient
(as judged by the investigator), current or previous drug or
alcohol abuse within the previous 2 years, and pregnancy.
3.3. Assessments. Patient data were collected at baseline and
at 3 and 6 months (±2 weeks) after enrolment. Demographic
data included age, sex, body weight, height, blood pressure,
body-mass index (BMI), waist and hip circumferences (used
to calculate the waist : hip (W :H) ratio), education level, and
place of residence. Data were also acquired on clinical char-
acteristics, including completion of training in diabetes self-
management, participation in regular physical exercise,
intake of an individually adjusted diet, participation in
SMBG, insulin regimen, history of T2DM that led to insulin
prescription, previous treatment with OAAs and insulin
before initiation of Gla-300 (including type of regimen: basal,
basal/bolus, or insulin mixture), and current treatment pre-
scribed after switch to insulin Gla-300, including use of
short-acting insulin(s) and OAAs.
Analysed parameters included change from baseline in
body weight and waist and hip circumference at 3 and 6
months (±2 weeks). In addition, changes in efficacy
parameters were evaluated over the same time period,
including HbA1c and fasting glycaemia (based on labora-
tory values or SMBG profile consisting of seven or fewer
points, as provided by the participant). The number of
episodes of symptomatic, symptomatic confirmed
(≤70mg/dL (≤3.9mmol/L)), severe, diurnal, or nocturnal
hypoglycaemia during the 4-week periods before Gla-300
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initiation and the 3- and 6-month assessments was
recorded. During the 6-month observation period, data
were also collected on all adverse events (AEs) and serious
adverse events (SAEs), including assessment of severity,
relation to Gla-300 treatment, and outcome.
3.4. Statistical Analysis. Statistical analysis of the collected
data was performed using descriptive measures according
to a predefined statistical analysis plan. Continuous variables
were described by patient numbers,mean ± SD, median, and
range. For categorical variables, absolute and percentage of
frequencies were determined. Paired, two-tailed Student’s t
-test was applied to test for differences in values between
baseline and after 3 and 6 months. The chi-squared test was
used for nonparametric variables.
4. Results
4.1. Patient Population. The study was conducted at 51 Polish
diabetes centres and diabetologist practices (although three
sites enrolled no participants). A total of 499 eligible patients
were enrolled, of whom 469 completed 6 months of observa-
tion during Gla-300 treatment. Participant flow is presented
in Table 1. The 30 participants who were not assessed at 3
and/or 6 months were excluded from the statistical analysis.
The characteristics of the 469 participants who completed 6
months of follow-up are presented in Table 2.
4.2. HbA1c, Fasting Glycaemia, and Daily Blood Glucose
Profile. In the primary endpoint analysis, 71.7% of partici-
pants achieved a decrease in HbA1c of ≥0.5% from baseline
to 6 months after switching from NPH insulin to Gla-300.
At 3 and 6 months, respectively, there were significant
decreases in mean HbA1c of 0.77% (±0.98) and 1.01%
(±1.12) (p < 0:00001 versus baseline) and fasting glycaemia
of 32mg/dL and 37mg/dL (p < 0:00001 versus baseline).
Furthermore, a consistent decrease in mean glycaemia values
in the daily profile was noted during 6 months of observation
(Table 3). As glycaemia profile data collection was not oblig-
atory and was provided for only 44.8% of participants at dif-
ferent time points, these data were not analysed statistically.
4.3. Diabetes Treatment Adjustment during Observation.
Before switching to Gla-300 due to uncontrolled HbA1c
(≥8%), all enrolled patients were treated with NPH insulin
(including NPH being the basal component of premixed for-
mulation) with or without concomitant OAA administra-
tion. Prior to the switch, the mean dose of long-acting NPH
insulin was 38U (±22), the mean dose of short-acting insulin
was 32U (±20), and the mean total insulin dose was 61U
(±32). Metformin was administered concomitantly in
67.6% of participants (mean daily dose: 2370 ± 770mg),
whereas 13.2% received sulphonylureas. Less frequently used
OAAs included sodium-glucose transport protein-2 inhibi-
tors (6.6%), alpha-glucosidase inhibitors (2.3%), dipeptidyl
Table 1: Participant flow.
Participants n
Enrolled 499
Completed 6 months of observation 469
Discontinued (not assessed at 3 and/or 6 months) 30
Unknown reason for discontinuation 19
Incomplete data at baseline 13
Lost to follow-up 7
Switched to other insulin 2
Death 1
Inefficacy 1
Table 2: Participant characteristics.
Sex
Men, n (%) 222 (47.3)
Women, n (%) 247 (52.7)
Age (years), mean±SD 64:8 ± 9:1
Height (cm), mean±SD 167 ± 9
Body weight (kg), mean±SD 90:8 ± 17:4
BMI (kg/m2), mean±SD 32:5 ± 5:7
W/H ratio, mean±SD 0:99 ± 0:09
Blood pressure (mm Hg), mean 139/80
Duration of T2DM (years), mean±SD 14:4 ± 7:7
Training in diabetes management
since diagnosis∗, n (%)
Individual 304 (65)
Group 84 (18)
Self-education 112 (24)
None 56 (12)
Individualised diabetes diet, n (%)
Yes 178 (38)
No 291 (62)
Regular physical exercise (≥30minutes,
four times per week), n (%)
Yes 80 (17)
No 389 (83)
SMBG, n (%)
Yes 403 (86)
No 66 (14)
Place of residence, n (%)
Voivodeship capital 113 (24
Other city 211 (45)
Village 145 (31)
Education level, n (%)
University 56 (12)
High school 286 (61)
Elementary 127 (27)
Insulin NPH regimen, n (%)
Basal 130 (28)
Basal-bolus 331 (70)
Human regular premixed insulin 8 (2)
∗Multiple options could be recorded. BMI: body-mass index; NPH: neutral
protamine Hagedorn; SD: standard deviation; SMBG: self-monitoring of
blood glucose; T2DM: type 2 diabetes mellitus; W/H: waist : hip ratio.
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peptidase-4 inhibitors (1.5%), thiazolidinediones (0.9%), and
glucagon-like peptide-1 receptor agonists (0.2%).
There was a moderate increase in the doses of both Gla-
300 and short-acting insulins during the 6-month observa-
tion period, with an increase in the total insulin dose of
13% compared with baseline (Table 4). The relative decrease
in HbA1c versus the increase in Gla-300 dose is summarised
in Figure 1. Administration of OAAs slightly decreased dur-
ing the study (Table 5).
4.4. Change in BMI and W/H Ratio. Body weight, waist and
hip circumferences, and W/H ratio did not change signifi-
cantly during observation (Table 6).
4.5. Hypoglycaemia. The number of participants with ≥1
diurnal or nocturnal hypoglycaemia episode during the
previous 4 weeks decreased significantly from baseline at
3 and 6 months, as did the number with symptomatic
hypoglycaemia at night (p < 0:00001 versus baseline)
(Table 7). No severe hypoglycaemia was reported after a
switch to Gla-300. There was a nonsignificant trend for a
decrease in the rate of symptomatic confirmed hypoglycae-
mia at night versus baseline. The frequency of symptom-
atic and symptomatic confirmed hypoglycaemia at night
was reduced at 6 months versus baseline by 43% and
18% (NS), respectively (Table 8).
4.6. Safety. Thirty-seven AEs were reported in 29 partici-
pants, of which 11 were SAEs. According to investigator
assessment, 4 AEs were severe, 25 AEs were moderate, and
8 AEs were mild. One SAE resulted in death, due to acute cir-
culatory insufficiency. Another participant died due to pro-
gression of cancer 4 months after enrolment. As this
patient did not have an assessment at 3 months after inclu-
sion, the patient was considered lost to follow-up and the
event was not reported as an SAE. None of the reported AE
was considered as related to Gla-300 administration.
5. Discussion
This study is aimed at assessing the real-world effectiveness
of switching from NPH basal insulin to Gla-300 in patients
with T2DM. To our knowledge, it is the first large, prospec-
tive observational study addressing this issue. We found that
the switch from NPH insulin to Gla-300 resulted in a signif-
icant reduction in HbA1c of 1.01% at 6 months relative to
baseline. This improved glycaemic control was achieved with
only a moderate increase in the doses of both Gla-300 and
short-acting insulins during the 6-month observation period,
with an increase in total insulin dose of 13% versus baseline.
Body mass, waist and hip circumferences, and W/H ratio did
not change significantly. A crucial finding was that the num-
ber of participants with ≥1 hypoglycaemia episode decreased
significantly at 3 and 6 months compared with the 4-week
period before inclusion, as did the rate of symptomatic hypo-
glycaemia at night. Importantly, no severe hypoglycaemia
was reported during the entire observation period.
One of the few prior studies reporting on a direct switch
from NPH insulin to Gla-300 in at least a subset of partici-
pants was a prospective, observational, multicentre trial by
Seufert et al. [12]. Patients were switched from their current
basal insulin to Gla-300 due either to inadequate glycaemic
control or occurrence of hypoglycaemia. Baseline basal insu-
lins were insulin glargine 100 (53.0%), NPH insulin (21.9%),
insulin detemir (13.7%), or others (%). In the primary end-
point analysis, 27% of patients achieved a fasting plasma glu-
cose (FPG) target of <110mg/dL after 12 months.
Furthermore, 54% of patients achieved the combined end-
point of either FPG < 110mg/dL or an individualised HbA1c
target. The highest combined target achievement was
attained by patients switching from insulin detemir (63.5%)
or NPH insulin (59.0%). There was a reduced incidence of
hypoglycaemia, especially nocturnal episodes, while only
minor changes in weight occurred. The dose of Gla-300
increased from 0.30U/kg/day at baseline to 0.36U/kg/day
at month 12.
Overall, Seufert et al. showed general trends similar to
those of the present study, with a significant decrease in
HbA1c, reduction in hypoglycaemia rates, no significant
weight gain, and only a minor increase in insulin dose. The
major difference, however, was that the former study focused
on patients receiving basal insulin only (in combination with
oral agents), whereas our study also included patients on
basal and prandial insulins. In addition, the population
enrolled by Seufert et al. was heterogenous with respect to
oral agents and basal insulins used at baseline, with only a
small proportion of patients receiving NPH insulin.
Similarly, Gupta et al. reported the effect of switching to
insulin glargine 300 from other base insulins on clinical out-
comes in patients with type 2 diabetes [13]. This was a retro-
spective observational study using medical record data
obtained by a physician survey for part of which concerned
switching to treatment with Gla-300 from treatment with
another basal insulin. The daily dose of basal insulin was sig-
nificantly lower after switching to treatment with Gla-300
from treatment with another basal insulin (0.73U/kg vs.
0.58U/kg). The mean haemoglobin A1c level was signifi-
cantly lower after switching than before switching (-0.95 per-
centage points). Hypoglycemic events per patient-year were
significantly lower (relative risk 0.17). Unfortunately the
studied group was very heterogeneous with respect to ethnic-
ity, mode of treatment, and basal insulin used. A comparison
to our study does not make too much sense since patients
switching to glargine 300 from NPH insulin were excluded
Table 3: HbA1c and glycaemia (fasting and daily profile
measurements).
Parameter, mean (SD) Baseline Month 3 Month 6
HbA1c (%) 9.19 (1.11) 8.38 (1.12)∗ 8.17 (1.17)∗
Glycaemia (mg/dL)
Fasting 178 (46) 146 (38)∗ 141 (41)∗
After breakfast 199 (55) 168 (44) 166 (42)
Before lunch 174 (54) 146 (43) 146 (45)
After lunch 210 (64) 183 (51) 178 (48)
After dinner 177 (51) 155 (51) 152 (46)
Before sleep 189 (57) 158 (49) 156 (45)
∗p < 0:00001 versus baseline. SD: standard deviation.
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from the analysis. In addition, the studied population was
characterized with much higher BMI as compared to ours.
Hidvegi et al. reported a 6-month, prospective, multi-
centre, noninterventional, observational, single-arm study
evaluating the effectiveness of Gla-300 when used as a part
of basal/bolus therapy in patients with T2DM [14].
Patients switching from human insulin-based basal/bolus
therapy to Gla-300-/insulin glulisine-based treatment were
eligible. Compared with baseline, after 6 months of ther-
apy, HbA1c decreased by 1.36%, with no weight gain,
while total insulin dose increased moderately by 9%, which
was entirely a result of Gla-300 uptitration. The mean
number of hypoglycaemia events per patient per year
Table 4: Gla-300, short-acting and total insulin doses during observation.
Insulin dose (U), mean (SD) Baseline Month 3 Month 6
Gla-300 26 (11) 29 (12) 31 (13)
Short-acting insulin (human regular or analogue) 44 (22) 47 (23) 48 (25)
Total 61 (32) 67 (34) 69 (35)
Gla-300: insulin glargine 300 U/mL; SD: standard deviation.
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Figure 1: Relative changes in HbA1c versus Gla-300 dose in the study population. Blue line: glargine 300 doses at baseline, 3 months, and 6
months. Green line: HbA1c values at baseline, 3 months, and 6 months.
Table 5: Change in concomitant OAA administration during observation.
Patients, n (%) Before switch Baseline Month 3 Month 6
Metformin 317 (67.6) 311 (66.3) 308 (65.7) 308 (65.7)
Metformin in combination 10 (2.1) 14 (3.0) 11 (2.3) 12 (2.6)
Sulphonylureas 62 (13.2) 50 (10.7) 49 (10.4) 44 (9.4)
Alpha-glucosidase inhibitors 13 (2.8) 11 (2.3) 9 (1.9) 10 (2.1)
DPP-4 inhibitors 12 (2.6) 7 (1.5) 4 (0.9) 4 (0.9)
SGLT-2 inhibitors 31 (6.6) 34 (7.2) 32 (6.8) 36 (7.7)
Thiazolidinediones 4 (0.9) 3 (0.6) 4 (0.9) 6 (1.3)
GLP-1 receptor agonists 1 (0.2) 1 (0.2) 1 (0.2) 0
DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; OAA: oral antidiabetic agent; SGLT-2: sodium-glucose transport protein-2.
Table 6: Change in weight, BMI, waist and hip circumferences, and
W/H ratio during observation.
Parameter, mean (SD) Baseline Month 3 Month 6
Body weight (kg) 90.8 (17.4) 90.7 (17.3) 90.5 (17.2)
BMI (kg/m2) 32.5 (19.0) 32.5 (19.0) 32.5 (19.0)
Waist (cm) 110 (15) 109 (15) 109 (15)
Hip (cm) 111 (14) 111 (14) 112 (14)
W/H ratio 0.99 (0.09) 0.98 (0.08) 0.98 (0.08)
BMI: body-mass index; SD: standard deviation; W/H: waist : hip ratio.
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decreased from 9.76 before the study by 2.3 from baseline
to month 6. These data are broadly consistent with the
present study. However, it should be emphasised that Hid-
vegi et al. included a population that was homogenous
with regard to types of insulin and model of therapy used
at baseline. In contrast, although all participants in our
study received NPH insulin, it was used in different types
of regimen and combined with different prandial insulins.
Other available data comparing Gla-300 vs. NPH insulin
provide consistent results regarding hypoglycaemia risk but
variable findings with respect to HbA1c. In a recent network
meta-analysis, Freemantle et al. found that, compared with
NPH insulin, Gla-300 provided a comparable change in
HbA1c and body weight, with a significantly lower nocturnal
hypoglycaemia rate (risk ratio: 0.18; 95% confidence interval:
0.05 to 0.55) [15]. The effect on hypoglycaemia risk was con-
sistent with our findings. The lack of effect on HbA1c could
be explained by the inclusion in the network meta-analysis
of only randomised controlled trials, a majority of which
followed a treat-to-target design. In contrast, the present
study was based on the use of two sequential therapies.
It is difficult to directly compare our data with that of pre-
vious studies of the effectiveness and safety of Gla-300, since
most prior reports have compared this agent with insulin
glargine 100U/mL or other insulin analogues. However,
despite the differences in study designs, our study should be
discussed in the context of selected previous analyses. For
example, EDITION 1 was a multicentre, open-label,
parallel-group study of patients with T2DM receiving cur-
rent basal therapy with either insulin glargine 100U/mL or
NPH insulin, together with mealtime insulins [16]. Partici-
pants were randomised to receive once-daily injections of
either Gla-300 or insulin glargine 100U/mL. At the end of
the observation period, HbA1c reduction was equivalent
between regimens, but fewer participants reported one or
more confirmed or severe nocturnal hypoglycaemic events
between week 9 and month 6 with Gla-300. However, in con-
trast to our study, daily basal insulin dose in EDITION 1
increased from 0.67U/kg/day to 0.97U/kg/day after 6
months. Mealtime insulin doses increased slightly in the first
2 weeks but were unchanged from baseline thereafter. In
addition, unlike the present study, EDITION 1 reported an
increase in body weight of 0.9 kg in both treatment groups.
This difference could be explained by the very rigid titration
rules in EDITION 1, compared with the more flexible
approach to titration adopted in real-world practice. How-
ever, glycaemic control at the end of our study (mean HbA1c:
8.17%) was far from optimal and even higher doses of Gla-
300 would be required to meet therapeutic targets. Other fac-
tors potentially contributing to the differences in insulin dose
and body weight outcomes between EDITION 1 and the
present study are the far higher BMI (36.6 versus
32.5 kg/m2, respectively) and the much greater total daily
insulin dose at baseline (126.3 versus 61.0U, respectively).
Pettus et al. recently reported an interesting study that
applied conventional and advanced analytical approaches to
model, predict, and compare hypoglycaemia rates in patients
with T2DM receiving Gla-300, or first-generation (insulin
glargine 100U/mL or insulin detemir) or second-generation
(insulin degludec) basal insulin analogues, utilising a large,
real-world database [17]. The analysis showed that rates of
severe hypoglycaemia were approximately 50% lower with
Gla-300 versus insulin glargine 100U/mL or insulin detemir
in insulin-naïve individuals, and 30% lower versus insulin
detemir in patients switched from basal insulin. Like our
study, this analysis showed a reduction in hypoglycaemia risk
Table 7: Patients with ≥1 episode of hypoglycaemia during the 4 weeks preceding baseline and assessments at 3 and 6 months.
Patients, n/total (%) Baseline Month 3 Month 6
Patients with hypoglycaemia 115/469 (24.5) 66/469 (14.1)^ 61/469 (13.0)∗∗
Severe∗
Day 2/115 (1.7) 0 0
Night 3/115 (2.6) 0 0
Symptomatic∗
Day 69/115 (60.0) 44/66 (66.7) 41/61 (67.2)
Night 76/115 (66.1) 18/66 (27.3)∗∗ 9/61 (14.8)∗∗
Symptomatic confirmed∗
Day 50/115 (43.5) 46/66 (69.7) 50/61 (82.0)
Night 47/115 (40.9) 17/66 (25.8)^^ 17/61 (27.9)∗∗∗
∗The total number of patients with hypoglycaemia at each assessment was used as the denominator for calculating the percentages; ∧p < 0:0001, ∗∗p < 0:00001,
∧∧p < 0:0407, and ∗∗∗p < 0:0880 versus baseline (chi-squared test).
Table 8: Number of symptomatic and symptomatic confirmed
hypoglycaemia episodes per patient (mean ± SD), among those
with ≥1 episode of hypoglycaemia during the 4 weeks preceding
baseline and assessments at 3 and at 6 months.
Hypoglycaemia Baseline Month 3 Month 6
Symptomatic
Day 2.5 (1.8) 2.2 (1.3) 2.3 (1.5)
Night 2.3 (2.0) 1.8 (1.0) 1.3 (0.7)∗
Symptomatic confirmed
Day 1.8 (1.0) 1.8 (1.1) 1.8 (1.1)
Night 1.7 (0.9) 1.9 (1.0) 1.4 (0.6)∗
SD: standard deviation. ∗NS (t-test).
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with Gla-300, but more detailed comparisons are precluded
by differences in study design and the absence of patients
on NPH insulin in the study by Pettus et al.
To summarise, while there is strong evidence that switch-
ing from NPH insulin to Gla-300 in patients with T2DM
decreases hypoglycaemia risk without causing weight gain,
data from randomised controlled trials are inconsistent
regarding improvement in HbA1c. There is a lack of real-life,
prospective, observational data comparing clinical effective-
ness of NPH insulin vs. Gla-300, which is in part addressed
by our study.
6. Conclusions
This large, prospective, observational study shows that a
direct switch from NPH insulin to Gla-300 results in a signif-
icant improvement in diabetes control (as reflected in
HbA1c) and a reduction of the number of patients experienc-
ing ≥1 hypoglycaemia, without an increase in body weight,
which comes at the cost of only a moderate increase in insu-
lin dose. Gla-300 is a safe and effective therapeutic option in
patients with T2DM who are uncontrolled on other insulins.
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